MALVERN, PA — Uniquity Bio plans to begin a pivotal Phase 3 trial of its experimental esophageal disease treatment in early 2027 after reporting statistically significant improvements in…
MALVERN, PA — Uniquity Bio plans to begin a pivotal Phase 3 trial of its experimental esophageal disease treatment in early 2027 after reporting statistically significant improvements in swallowing symptoms …
Source disclosure
This is a source-linked briefing. Read the original report from Mychesco .